Aaltomaa S et al. Expression of Ki-67, cyclin D1 and apoptosis markers correlated with survival in prostate cancer patients treated by radical prostatectomy. Anticancer Res 2006;26(6C):4873-8. Abstract

Augustin H et al. Shift of tumor features in patients with clinically localized prostate cancer undergoing radical prostatectomy since the beginning of the PSA era. Wien Klin Wochenschr 2006;118(11-12):348-54. Abstract

Bastide C et al. The role of radical prostatectomy in patients with clinically localized prostate cancer and a prostate-specific antigen level >20 ng/ml. Prostate Cancer Prostatic Dis. 2006;9(3):239-44;[Epub 2006]. Abstract

Berry W, Eisenberger M. Achieving treatment goals for hormone-refractory prostate cancer with chemotherapy. Oncologist 2005;10 (Suppl 3):30-9. Abstract

Bruchovsky N et al. Locally advanced prostate cancer-biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy. Cancer 2007;[Epub ahead of print]. Abstract

Chen BT, Wood DP Jr. Salvage prostatectomy in patients who have failed radiation therapy or cryotherapy as primary treatment for prostate cancer. Urology 2003;62(Suppl 1):69-78. Abstract

D’Amico A et al. Prostate-specific antigen failure and all cause mortality. Proc AUA 2006;Abstract 663.

D’Amico AV et al. Surrogate end point for prostate cancer specific mortality in patients with nonmetastatic hormone refractory prostate cancer. J Urol 2005;173(5):1572-6. Abstract

D’Amico AV et al. Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. J Urol 2004;172(5 Pt 2):S42-6. Abstract

Dreicer R, Carducci M. E-1899: An Eastern Cooperative Oncology Group study comparing ketoconazole plus hydrocortisone with docetaxel plus estramustine for asymptomatic, androgen-independent, nonmetastatic prostate cancer patients with rising PSA levels. Rev Urol 2003;5(Suppl 2):35-41. Abstract

Fan KH et al. Preliminary treatment results of intensity-modulated radiotherapy for prostate cancer. Chang Gung Med J 2006;29(3):313-24. Abstract

Fleming MT et al. Post-therapy changes in PSA as an outcome measure in prostate cancer clinical trials. Nat Clin Pract Oncol 2006;3(12):658-67. Abstract

Freedland SJ et al. The prostatic specific antigen era is alive and well: Prostatic specific antigen and biochemical progression following radical prostatectomy. J Urol 2005;174(4 Pt 1):1276-81. Abstract

Goodin S et al. Effect of docetaxel in patients with hormone-dependent prostate-specific antigen progression after local therapy for prostate cancer. J Clin Oncol 2005;23(15):3352-7. Abstract

Gore J, Rajfer J. Rising PSA during testosterone replacement therapy. Rev Urol 2004;6(Suppl 6):41-3. Abstract

Harris KA, Small EJ. Hormonal treatment for prostate cancer. Expert Opin Investig Drugs 2001;10(3):493-510. Abstract

Heng DY, Chi KN. Prednisone monotherapy in asymptomatic hormone refractory prostate cancer. Can J Urol 2006;(6):3335-9. Abstract

Heymann JJ et al. Phase II study of neoadjuvant androgen deprivation followed by external-beam radiotherapy with 9 months of androgen deprivation for intermediate- to high-risk localized prostate cancer. J Clin Oncol 2007;25(1):77-84. Abstract

Hussain A et al. Docetaxel followed by hormone therapy in men experiencing increasing prostate-specific antigen after primary local treatments for prostate cancer. J Clin Oncol 2005;23(12):2789-96. Abstract

Kang TY et al. Functional heterogeneity of prostatic intraepithelial neoplasia: The duration of hormonal therapy influences the response. BJU Int 2007;[Epub ahead of print]. Abstract

Kawakami J et al. Androgen-deprivation therapy as primary treatment for localized prostate cancer: Data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). Cancer 2006;106(8):1708-14. Abstract

Kirkpatrick JP, Anscher MS. Radiotherapy for locally recurrent prostate cancer. Clin Adv Hematol Oncol 2005;3(12):933-42. Abstract

Konstantinos H. Prostate cancer in the elderly. Int Urol Nephrol 2005;37(4):797-806. Abstract

Kumar S et al. Neo-adjuvant and adjuvant hormone therapy for localized and locally advanced prostate cancer. Cochrane Database Syst Rev 2006;(4):CD006019. Abstract

Kupelian PA et al. Factors affecting recurrence rates after prostatectomy or radiotherapy in localized prostate carcinoma patients with biopsy Gleason score 8 or above. Cancer 2002;95(11):2302-7. Abstract

Martin J et al. Low and intermediate risk prostate cancer — Role of hormonal therapy with external beam radiation therapy. Can J Urol 2006;13(Suppl 2):63-7. Abstract

Merrick GS et al. Brachytherapy in men aged < or = 54 years with clinically localized prostate cancer. BJU Int 2006;98(2):324-8. Abstract

Mike S et al. Chemotherapy for hormone-refractory prostate cancer. Cochrane Database Syst Rev 2006;(4):CD005247. Abstract

Milecki P et al. Radiotherapy combined with hormonal therapy (RT-HT) in prostate cancer patients with low, intermediate, and high risk of biochemical recurrence: Perspective and therapeutic gain analysis. Neoplasma 2007;54(1):7-15. Abstract

Moul JW, Ward JF. Management of the patient with a rising PSA alone. Hematol Oncol Clin North Am 2006;20(4):897-908. Abstract

Penson D et al. Use of prostate-specific antigen in the follow-up of patients with localized prostate cancer: results of a nationwide survey of urologists.Urology 2006;68(1):80-4; [Epub 2006]. Abstract

Pound CR et al. Evaluation and treatment of men with biochemical prostate-specific antigen recurrence following definitive therapy for clinically localized prostate cancer. Rev Urol 2001;3(2):72- 84. Abstract

Roach M 3rd et al. Staging for prostate cancer: Time to incorporate pretreatment prostate-specific antigen and Gleason score? Cancer 2007;109(2):213-20. Abstract

Rodrigues NA et al. Predictors of mortality after androgen-deprivation therapy in patients with rapidly rising prostate-specific antigen levels after local therapy for prostate cancer. Cancer 2006;107(3):514-20. Abstract

Ryan CJ. Secondary hormonal manipulations in prostate cancer. Hematol Oncol Clin North Am 2006;20(4):925-34. Abstract

Scher HI et al. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: Recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 2004;22(3):537-56. Abstract

Simmons MN et al. Natural history of biochemical recurrence after radical prostatectomy: Risk assessment for secondary therapy. Eur Urol 2007;[Epub ahead of print]. Abstract

Slawin KM. Radiation therapy after radical prostatectomy: Why patience is a virtue! The case for salvage radiation therapy. Rev Urol 2002;4(2):90-4. Abstract

Small EJ et al. Serum prostate-specific antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients: Association with progression-free survival, pain end points, and survival. J Clin Oncol 2001;19(5):1304-11. Abstract

Smith MR et al. Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy. J Clin Oncol 2006;24(18):2723-8. Abstract

Smith MR et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol 2005;23(13):2918-25. Abstract

Truong PT et al. Prospective evaluation of the prevalence and severity of fatigue in patients with prostate cancer undergoing radical external beam radiotherapy and neoadjuvant hormone therapy. Can J Urol 2006;13(3):3139-46. Abstract

Vargas C et al. High-dose radiation employing external beam radiotherapy and high-dose rate brachytherapy with and without neoadjuvant androgen deprivation for prostate cancer patients with intermediate- and high-risk features. Prostate Cancer Prostatic Dis 2006;9(3):245-53;[Epub 2006]. Abstract

Ward JF, Moul JW. Rising prostate-specific antigen after primary prostate cancer therapy. Nat Clin Pract Urol 2005;2(4):174-82. Abstract

Williams SA et al. Does PSA play a role as a promoting agent during the initiation and/ or progression of prostate cancer? Prostate 2007;67(3):312-29. Abstract

Zampino MG et al. Vinorelbine-based chemotherapy in hormone-refractory prostate cancer. Anticancer Res 2006;26(3B):2375-80. Abstract

Zelefsky MJ et al. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys 2007;67(2):327- 33;[Epub 2006]. Abstract

Zelefsky MJ et al. Evaluation of postradio-therapy PSA patterns and correlation with 10-year disease free survival outcomes for prostate cancer. Int J Radiat Oncol Biol Phys 2006;66(2):382-8. Abstract